Fig. 1From: Identifying FDA-approved drugs with multimodal properties against COVID-19 using a data-driven approach and a lung organoid model of SARS-CoV-2 entryOur analysis strategy. We used a connectivity mapping approach in combination with chemoinformatic analyses and in vitro tests using a lung organoid model, to investigate drugs with putative multimodal effects against SARS-CoV-2/COVID-19. Created with Biorender.comBack to article page